Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharmaceuticals Regulatory News (FARN)

Share Price Information for Faron Pharmaceuticals (FARN)

Share Price is delayed by 15 minutes
Get Live Data
46.00    0.00 (0.00%)
Bid:
45.00
Ask:
47.00
Spread: 2.00 (4.444%)
Market Cap: £91.78m
FARN Live PriceLast checked at - London Stock Exchange

Intraday Faron Pharmaceuticals Share Chart

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

24 Mar 2026 16:30

Faron Pharmaceuticals Ltd | Company announcement | March 24, 2026 at 18:30:00 EET

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:Faron Pharmaceuticals Ltd
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuerx
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rightsx
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) iii: Dividend payments in kind.x
3. Details of person subject to the notification obligation iv
NameTimo Syrj¤l¤
City and country of registered office (if applicable)Monaco
4. Full name of shareholder(s) (if different from 3.) v
NameAcme Investments SPF Sarl
City and country of registered office (if applicable)Luxembourg
5. Date on which the threshold was crossed or reached vi:20.03.2026
6. Date on which issuer notified (DD/MM/YYYY):23.03.2026
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A)% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)Total of both in % (8.A + 8.B)Total number of voting rights held in issuer (8.A + 8.B) vii
Resulting situation on the date on which threshold was crossed or reached12.69%14.697.112
Position of previous notification (ifapplicable)13.90%16.093.129
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type ofsharesISIN code (if possible)Number of voting rights ix% of voting rights
Direct(DTR5.1)Indirect(DTR5.2.1)Direct(DTR5.1)Indirect(DTR5.2.1)
FI40001533095.621.0959.076.0174.85%7.84%
SUBTOTAL 8. A14.697.11212.69%
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrumentExpirationdate xExercise/ Conversion Period xiNumber of voting rights that may be acquired if the instrument isexercised/converted.% of voting rights
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrumentExpirationdate xExercise/ Conversion Period xiPhysical or cashSettlement xiiNumber of voting rights% of voting rights
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation (please mark theapplicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii
Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xivX
Name xv% of voting rights if it equals or is higher than the notifiable threshold% of voting rights through financial instruments if it equals or is higher than the notifiable thresholdTotal of both if it equals or is higher than the notifiable threshold
Timo Syrj¤l¤ (Direct)4.85%4.85%
Acme Investments SPF Sarl (Indirect)7.84 %7.84 %
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information xvi
Place of completionMonaco
Date of completion23.3.2026
Date   Source Headline
28th May 201912:27 pmRNSResults of AGM
24th May 20199:32 amRNSAGM update, Board & management changes
22nd May 201912:51 pmRNSGrant of Options
21st May 20199:21 amRNSHolding(s) in Company
16th May 20199:16 amRNSHolding(s) in Company
14th May 20197:01 amRNSHoldings in Company
14th May 20197:00 amRNSShare Subscription and Issue of Equity
7th May 20197:05 amRNSNotice of AGM
7th May 20197:00 amRNSFinal Results for the year ended 31 December 2018
2nd May 20195:20 pmRNSStatement regarding Price Movement
2nd May 20192:05 pmRNSSecond Price Monitoring Extn
2nd May 20192:00 pmRNSPrice Monitoring Extension
29th Apr 20197:00 amRNSResults from the Japanese Phase III study
25th Apr 20194:09 pmRNSHolding(s) in Company
12th Apr 20191:20 pmRNSHolding(s) in Company
11th Apr 20197:00 amRNSFirst expansion cohort for MATINS trial part 2
10th Apr 201911:41 amRNSHolding(s) in Company
5th Apr 20197:00 amRNSNotice of Results
2nd Apr 20199:23 amRNSHoldings in Company
29th Mar 20197:00 amRNSHolding(s) in Company
28th Mar 201912:54 pmRNSResults of the Placing and Subscription
26th Mar 20193:31 pmRNSResult of Placing and Issue Price
26th Mar 20197:00 amRNSProposed Placing to raise approximately EUR 3m
21st Feb 20197:00 amRNSMATINS study update
13th Feb 20198:57 amRNSNew data published by Clinical Cancer Research
19th Dec 20187:00 amRNSTraumakine update - YODA results
14th Dec 201811:20 amRNSFirst patient dosed in phase I/II MATINS study
11th Dec 20184:26 pmRNSHolding(s) in Company
5th Dec 20187:00 amRNSPatient subgroup identified from INTEREST trial
3rd Dec 20187:00 amRNSFaron receives CTA approval for Clevegen
6th Nov 20183:52 pmRNSPDMR Dealings
23rd Oct 201811:05 amRNSSecond Price Monitoring Extn
23rd Oct 201811:00 amRNSPrice Monitoring Extension
23rd Oct 20189:06 amRNSSecond Price Monitoring Extn
23rd Oct 20189:00 amRNSPrice Monitoring Extension
22nd Oct 20183:00 pmRNSINTEREST trial update presented at ESICM
18th Sep 20189:23 amRNSDirector/PDMR Shareholding
17th Sep 20187:00 amRNSFaron announces CTA filing for Clevegen
13th Sep 20187:00 amRNSInterim Results
12th Sep 20187:00 amRNSNew data published on Clever-1 function
8th Aug 201811:05 amRNSSecond Price Monitoring Extn
8th Aug 201811:00 amRNSPrice Monitoring Extension
8th Aug 20187:00 amRNSNotice of Interim Results
9th Jul 20188:45 amRNSHolding(s) in Company
28th Jun 20187:00 amRNSClevegen successful toxicity studies
22nd Jun 20187:00 amRNSHoldings in Company
21st Jun 20183:58 pmRNSDirector/PDMR Shareholding
21st Jun 20189:00 amRNSPrice Monitoring Extension
21st Jun 20187:40 amRNSDirector/PDMR Shareholding
20th Jun 20182:05 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.